![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Merck |
---|---|
Information provided by: | Merck |
ClinicalTrials.gov Identifier: | NCT00092027 |
This study is to assess the safety and tolerability of MK0217 being evaluated to treat women with postmenopausal osteoporosis.
Condition | Intervention | Phase |
---|---|---|
Postmenopausal Osteoporosis |
Drug: MK0217, alendronate sodium/Duration of Treatment: 6 months Drug: Comparator: placebo / Duration of Treatment: 6 months |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Compare the Safety and Tolerability of an Oral Buffered Solution of Alendronate Sodium 70 Mg Once-Weekly Versus Placebo for the Treatment of Osteoporosis in Postmenopausal Women |
Estimated Enrollment: | 400 |
Study Start Date: | March 2003 |
Ages Eligible for Study: | 25 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 2004_017 |
Study First Received: | September 21, 2004 |
Last Updated: | July 6, 2006 |
ClinicalTrials.gov Identifier: | NCT00092027 |
Health Authority: | United States: Food and Drug Administration |
Musculoskeletal Diseases Alendronate Osteoporosis, Postmenopausal |
Osteoporosis Bone Diseases, Metabolic Bone Diseases |
Physiological Effects of Drugs Bone Density Conservation Agents Pharmacologic Actions |